These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 7845670)

  • 1. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
    Mansur CP; Marcus B; Dalal S; Androphy EJ
    Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP.
    Sherman L; Itzhaki H; Jackman A; Chen JJ; Koval D; Schlegel R
    Virology; 2002 Jan; 292(2):309-20. PubMed ID: 11878933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells.
    Pim D; Storey A; Thomas M; Massimi P; Banks L
    Oncogene; 1994 Jul; 9(7):1869-76. PubMed ID: 8208532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
    Giovane C; Trave G; Briones A; Lutz Y; Wasylyk B; Weiss E
    J Mol Recognit; 1999; 12(2):141-52. PubMed ID: 10398405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation.
    Thomas M; Massimi P; Jenkins J; Banks L
    Oncogene; 1995 Jan; 10(2):261-8. PubMed ID: 7838526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
    Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6.
    Crook T; Ludwig RL; Marston NJ; Willkomm D; Vousden KH
    Virology; 1996 Mar; 217(1):285-92. PubMed ID: 8599213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
    Pim D; Banks L
    Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
    Pim D; Massimi P; Banks L
    Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6.
    Molinari M; Milner J
    Oncogene; 1995 May; 10(9):1849-54. PubMed ID: 7753560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6.
    Inoue T; Oka K; Yong-Il H; Vousden KH; Kyo S; Jing P; Hakura A; Yutsudo M
    Mol Carcinog; 1998 Mar; 21(3):215-22. PubMed ID: 9537653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence.
    Thomas M; Massimi P; Banks L
    Oncogene; 1996 Aug; 13(3):471-80. PubMed ID: 8760288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.
    Nominé Y; Masson M; Charbonnier S; Zanier K; Ristriani T; Deryckère F; Sibler AP; Desplancq D; Atkinson RA; Weiss E; Orfanoudakis G; Kieffer B; Travé G
    Mol Cell; 2006 Mar; 21(5):665-78. PubMed ID: 16507364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
    Mantovani F; Banks L
    Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of transcriptional activation by the bovine papillomavirus type 1 E6.
    Chen JJ; Hong Y; Androphy EJ
    Virology; 1997 Sep; 236(1):30-6. PubMed ID: 9299614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300.
    Patel D; Huang SM; Baglia LA; McCance DJ
    EMBO J; 1999 Sep; 18(18):5061-72. PubMed ID: 10487758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
    Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
    Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6.
    Gu Z; Pim D; Labrecque S; Banks L; Matlashewski G
    Oncogene; 1994 Feb; 9(2):629-33. PubMed ID: 8290274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
    Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
    Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between the HPV-16 E2 transcriptional activator and p53.
    Massimi P; Pim D; Bertoli C; Bouvard V; Banks L
    Oncogene; 1999 Dec; 18(54):7748-54. PubMed ID: 10618715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.